Literature DB >> 14642826

17beta-Estradiol extends ischemic thresholds and exerts neuroprotective effects in cerebral subcortex against transient focal cerebral ischemia in rats.

Tao Fan1, Shao-Hua Yang, Erik Johnson, Barbara Osteen, Ronald Hayes, Arthur L Day, James W Simpkins.   

Abstract

Neuroprotective effects of estrogens are demonstrated consistently in the cerebral cortex, but not in subcortical areas. In the present study, transient middle cerebral artery occlusions (MCAO) were induced for various duration, and protective effects of estrogen treatment on the cerebral cortex and subcortex were evaluated. MCAO was induced for 30, 40 or 60 min in ovariectomized rats. Animals were treated with 17beta-estradiol (E2) or vehicle (OVX) 2 h before MCAO and sacrificed 24 h after the indicated duration of MCAO. Ischemic lesion was evaluated by 2,3,5-triphenyltetrazolium chloride staining, hematoxylin and eosin staining, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. E2 treatment reduced the magnitude and delayed the appearance of the total ischemic lesion area and largely prevented TUNEL staining in the cortex. In the subcortex, E2 treatment prevented the ischemic lesion in the 30-min group, reduced lesion area in the 40-min group, but had no effect on ischemic lesion area in the 60-min group. E2 treatment significantly decreased apoptotic cell number in the subcortical area at 30 and 40 min, but not at 60 min of MCAO. This study demonstrated that estrogen treatment can protect the cerebral subcortex in a severity-dependent manner, suggesting that the lack of protective effects of estrogen treatment in the subcortex is not due to the lack of estrogen receptors. Further, this study indicates that estrogens could be used as a neuroprotectant to prolong the therapeutic window of thrombolysis and prolong the time of cerebral circulation intervention for neurosurgical procedure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642826     DOI: 10.1016/j.brainres.2003.07.006

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke.

Authors:  Farida Sohrabji; Amutha Selvamani; Robyn Balden
Journal:  Horm Behav       Date:  2012-06-19       Impact factor: 3.587

2.  17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia.

Authors:  Mingchang Li; Zhan Zhang; Weiyun Sun; Raymond C Koehler; Judy Huang
Journal:  Neurobiol Dis       Date:  2011-07-18       Impact factor: 5.996

Review 3.  Neuroprotective action of acute estrogens: animal models of brain ischemia and clinical implications.

Authors:  Tomoko Inagaki; Anne M Etgen
Journal:  Steroids       Date:  2013-02-04       Impact factor: 2.668

4.  A high soy diet reduces programmed cell death and enhances bcl-xL expression in experimental stroke.

Authors:  T Lovekamp-Swan; M Glendenning; D A Schreihofer
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

5.  Sex differences in XIAP cleavage after traumatic brain injury in the rat.

Authors:  Helen M Bramlett; Ofelia Furones-Alonso; George Lotocki; Alejandra Rodriguez-Paez; Juliana Sanchez-Molano; Robert W Keane
Journal:  Neurosci Lett       Date:  2009-06-09       Impact factor: 3.046

6.  Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants.

Authors:  Paramjit Kaur; Parmeet K Jodhka; Wendy A Underwood; Courtney A Bowles; Nancyellen C de Fiebre; Christopher M de Fiebre; Meharvan Singh
Journal:  J Neurosci Res       Date:  2007-08-15       Impact factor: 4.164

7.  Impact of methodology on estrogens' effects on cerebral ischemia in rats: an updated meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg
Journal:  BMC Neurosci       Date:  2014-02-04       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.